Results for tag: "Pradaxa"

Pradaxa is a hematological drug used to prevent stroke and blood clots in people with atrial fibrillation (AF). It is a direct thrombin inhibitor, meaning it works by blocking the activity of thrombin, a protein involved in the formation of blood clots. Pradaxa is the first and only direct thrombin inhibitor approved by the U.S. Food and Drug Administration (FDA). It is also approved in more than 100 countries worldwide. Pradaxa is used to reduce the risk of stroke and systemic embolism in patients with non-valvular AF. It is also used to treat and reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE). The Pradaxa market is highly competitive, with several major players offering similar products. These include Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, and Sanofi. Other companies in the market include Bayer, Merck, AstraZeneca, and GlaxoSmithKline. Show Less Read more